Search results for "ADENOCARCINOMA"

showing 10 items of 589 documents

Preoperative endoscopic pyloric balloon dilatation decreases the rate of delayed gastric emptying after Ivor–Lewis esophagectomy

2018

Delayed gastric emptying (DGE) after Ivor-Lewis esophagectomy occurs postoperatively in up to 50% of the patients. This pyloric dysfunction can lead to severe secondary complications postoperatively such as early aspiration, pneumonia or may even have an impact on anastomotic healing and therefore leakage. Early detection of DGE is essential to prevent further complications. The common treatment postoperatively is endoscopic pyloric balloon dilatation (EPBD) after symptoms already occurred. In our work, we analyzed patients who received a preoperative EPBD during the routine restaging endoscopy and compared those patients to a control group to analyze if preoperative EPBD may prevent postop…

AdultMalemedicine.medical_specialtyGastroparesisEsophageal Neoplasmsmedicine.medical_treatmentAdenocarcinomaAnastomosisBalloonBalloon dilatation03 medical and health sciencesPostoperative Complications0302 clinical medicineStatistical significancePreoperative CaremedicineHumansPylorusAgedNeoplasm StagingRetrospective StudiesAged 80 and overGastric emptyingmedicine.diagnostic_testbusiness.industryIncidence (epidemiology)GastroenterologyGeneral MedicineMiddle AgedDilatationSurgeryEndoscopyEsophagectomyGastric EmptyingEsophagectomy030220 oncology & carcinogenesisCarcinoma Squamous CellFemale030211 gastroenterology & hepatologybusinessDiseases of the Esophagus
researchProduct

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival…

2015

Summary Background We aimed to assess the effect of afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, randomised, phase 3 trials. Methods Previously untreated patients with EGFR mutation-positive stage IIIB or IV lung adenocarcinoma were enrolled in LUX-Lung 3 (n=345) and LUX-Lung 6 (n=364). These patients were randomly assigned in a 2:1 ratio to receive afatinib or chemotherapy (pemetrexed-cisplatin [LUX-Lung 3] or gemcitabine-cisplatin [LUX-Lung 6]), stratified by EGFR mutation (exon 19 deletion [del19], Leu858Arg, or other) and ethnic origin (LUX-Lung 3 only). We planned analyses of mature overall sur…

AdultMalemedicine.medical_specialtyGuanineLung NeoplasmsAfatinibPopulationMedizinPemetrexedNeutropeniaAdenocarcinomaAfatinibGastroenterologyDeoxycytidineGlutamatesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineMucositisHumansRociletinibeducationLung cancerSurvival rateAgedNeoplasm StagingAged 80 and overeducation.field_of_studybusiness.industryMiddle Agedmedicine.diseasePrognosisGemcitabineSurgeryErbB ReceptorsSurvival RatePemetrexedOncologyMutationQuinazolinesFemaleCisplatinbusinessmedicine.drugFollow-Up StudiesThe Lancet. Oncology
researchProduct

Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocar…

1994

Thirty-seven consecutive patients with advanced and/or metastatic gastric adenocarcinoma received a combination of 5-fluorouracil 600 mg/m2 on days 1, 8, 29, 36; epidoxorubicin 75 mg/m2 i.v. on days 1, 29; mitomycin C 10 mg/m2 i.v. on day 1. This cycle was repeated every 8 weeks. Out of a total of 34 evaluable patients, 2 (5.8%) had a complete response and 7 (20.6%) had a partial response with an overall median duration of 40 weeks (range 20-128). The median survival of responding patients was not reached after a mean follow-up of 76 weeks, while that of patients with no change and progressive disease was reached at 36 and 13 weeks respectively. Treatment was generally well tolerated with h…

AdultMalemedicine.medical_specialtyMitomycinmedicine.medical_treatmentAdenocarcinomaGastric Adenocarcinoma Chemotherapy Epidoxorubicin Mitomicin CGastroenterologyStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)Neoplasm MetastasisAgedEpirubicinAged 80 and overPharmacologyChemotherapybusiness.industryStomachPalliative CareMitomycin CCombination chemotherapyMiddle Agedmedicine.diseaseConfidence intervalSurgeryInfectious Diseasesmedicine.anatomical_structureOncologyFluorouracilAdenocarcinomaFemaleFluorouracilbusinessProgressive diseasemedicine.drug
researchProduct

Selective approach to the treatment of oesophageal cancer

1996

Abstract Between September 1985 and December 1994, 322 patients with oesophageal cancer were treated. Of the 190 patients who underwent operation, 173 had an oesophageal resection; in 124 this was performed as an abdominothoracic resection and in 49 by the transhiatal approach. The assessment of radicality after histological examination revealed a curative (R0) resection in 121 patients (70 per cent) and a palliative (R1-R2) resection in 52 (30 per cent). Prognosis was correlated with the extent of mediastinal lymph node dissection. In 77 patients with stage pT1–3 pN0–1 pM0 the 5-year survival rate was 40 per cent after abdominothoracic resection with two-field lymph node dissection and zer…

AdultMalemedicine.medical_specialtyPalliative careEsophageal Neoplasmsmedicine.medical_treatmentAdenocarcinomamedicineCarcinomaHumansLymph nodeSurvival rateAgedRetrospective StudiesAged 80 and overbusiness.industryMiddle AgedEsophageal cancerPrognosismedicine.diseaseSurvival AnalysisSurgeryDissectionmedicine.anatomical_structureLymphatic MetastasisMediastinal lymph nodeCarcinoma Squamous CellLymph Node ExcisionFemaleSurgeryLymphadenectomybusinessBritish Journal of Surgery
researchProduct

Lysosomal aspartic and cysteine proteinases serum levels in patients with pancreatic cancer or pancreatitis

1997

Lysosomal cathepsins D (CD), B (CB), and L (CL) serum levels were determined by immunoassays in patients with chronic (CHP) or acute (AP) pancreatitis and in patients with ductal pancreatic carcinoma (DPC) and correlated with some biological and clinical parameters of this tumor. CB serum concentrations significantly higher than those measured in healthy subjects (NS) were observed in CHP, AP, and DPC patients (p < 0.01). However, no significant difference was noted among these groups. Increased CL serum levels were evident only in cancer patients compared to NS, AP, or CHP groups (p < 0.05), while no difference was observed among these groups. Elevated CD serum values were observed i…

AdultMalemedicine.medical_specialtyPancreatic diseaseCA-19-9 AntigenEndocrinology Diabetes and MetabolismCathepsin LLysosomal proteinaseCathepsin DTumor markers.Cathepsin BEndocrinologyPancreatic cancerInternal medicineEndopeptidasesInternal MedicinemedicineCarcinomaAspartic Acid EndopeptidasesHumansAntigens Tumor-Associated CarbohydrateAgedAged 80 and overVHepatologybusiness.industryCarcinoma Ductal BreastCancerPancreatic cancerMiddle Agedmedicine.diseaseCathepsinsPancreatic NeoplasmsCysteine EndopeptidasesEndocrinologymedicine.anatomical_structurePancreatitisTumor progressionAdenocarcinomaPancreatitisFemalePancreasbusinessLysosomes
researchProduct

Mucinous cystadenomas and intraductal papillary mucinous tumors of the pancreas in magnetic resonance cholangiopancreatography.

2000

Background and Study Aims: In mucin-producing tumors of the pancreas, diagnosis using endoscopic retrograde cholangiopancreatography (ERCP) is limited to cystic formations that communicate with the main pancreatic duct. Magnetic resonance cholangiopancreatography (MRCP) is a new, sophisticated method which is currently under evaluation. The authors describe the usefulness of MRCP in diagnosis of mucin-producing tumors. Patients and Methods: Six patients with mucin-producing tumors were investigated using MRCP and ERCP. Imaging was compared with surgery and histopathological examinations. Results: Three patients were found to have mucinous cystadenomas (MC), two patients had intraductal papi…

AdultMalemedicine.medical_specialtyPancreatic diseaseCholangiographyCystadenoma MucinousmedicineHumansEndoscopy Digestive SystemCystadenocarcinomaMucinous cystadenomaAgedPancreatic ductMagnetic resonance cholangiopancreatographyEndoscopic retrograde cholangiopancreatographymedicine.diagnostic_testbusiness.industryGastroenterologyMiddle Agedmedicine.diseaseMagnetic Resonance ImagingPancreatic Neoplasmsmedicine.anatomical_structureFeasibility StudiesFemaleRadiologyPancreasbusinessCholangiographyEndoscopy
researchProduct

Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safet…

2007

Background: In daily clinical practice second-line chemotherapy (SLCT) is frequently given to patients with advanced pancreatic cancer failing gemcitabine-based first-line chemotherapy without solid scientific support. Patients and methods: A retrospective survey was carried out including 42 patients. Patients received standard FOLFOX4 regimen biweekly until progression or unacceptable toxicity. Results: Six partial responses (14%) and 16 stabilizations (38%) were recorded for a tumor growth control rate of 57%. The median time to progression (TtP) was 4 months (range 1–7 months), and median overall survival (OS) was 6.7 months (range 2–9 months). A stabilization of performance status (PS) …

AdultMalemedicine.medical_specialtyPancreatic diseaseOrganoplatinum Compoundsmedicine.medical_treatmentLeucovorinAdenocarcinomaInternal medicinePancreatic cancerAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansAgedRetrospective StudiesChemotherapyPerformance statusbusiness.industryCancerHematologyMiddle Agedmedicine.diseaseChemotherapy regimenGemcitabineDrug Resistance MultipleSurgeryPancreatic NeoplasmsFOLFOX4 regimen pancreatic carcinoma second-line chemotherapyRegimenOncologyChemotherapy AdjuvantDrug Resistance NeoplasmFemaleFluorouracilbusinessmedicine.drug
researchProduct

Total pancreatectomy: indications, operative technique, and results: a single centre experience and review of literature.

2010

The aims of this study were to identify the indications to perform a total pancreatectomy and to evaluate the outcome and quality of life of the patient who underwent this operation. A retrospective analysis of a prospective database, regarding all the patients who underwent total pancreatectomy from January 2006 to June 2009, was carried out. Perioperative and outcome data were analyzed in two different groups: ductal adenocarcinoma (group 1) and non-ductal adenocarcinoma (group 2). Twenty (16.9%) total pancreatectomies out of 118 pancreatic resections were performed. Seven (35.0%) patients were affected by ductal adenocarcinoma (group 1) and the remaining 13 (65.0%) by pancreatic diseases…

AdultMalemedicine.medical_specialtyPancreatic diseaseSURGERYmedicine.medical_treatmentNeuroendocrine tumorsTOTAL PANCREATECTOMYGastroenterologyPancreatectomyPostoperative ComplicationsTUMORPancreatic cancerInternal medicinemedicineHumansAgedPANCREASbusiness.industryPerioperativeMiddle Agedmedicine.diseasePancreaticoduodenectomyPancreatic cancer Pylorus preserving Spleen preservingSurgeryPancreatic NeoplasmsSettore MED/18 - Chirurgia GeneralePancreatectomyCHRONIC PANCREATITISPancreatitisAdenocarcinomaFemalebusinessUpdates in surgery
researchProduct

Are pancreatic calcifications specific for the diagnosis of chronic pancreatitis? A multidetector-row CT analysis

2009

Aim To retrospectively establish the most frequently encountered diagnoses in patients with pancreatic calcifications and to investigate whether the association of certain findings could be helpful for diagnosis. Materials and methods One hundred and three patients were included in the study. The location and distribution of calcifications; presence, nature, and enhancement pattern of pancreatic lesions; pancreatic atrophy and ductal dilatation were recorded. Differences between patients with chronic pancreatitis and patients with other entities were compared by using Fisher's exact test. Results Patients had chronic pancreatitis ( n =70), neuroendocrine tumours ( n =14), intraductal papill…

AdultMalemedicine.medical_specialtyPancreatic diseaseSensitivity and SpecificityGastroenterologyCalcinosisPancreatitis ChronicInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingPancreatitis chronicPancreatic calcificationAgedRetrospective StudiesAged 80 and overIntraductal papillary mucinous neoplasmbusiness.industryPancreatic DuctsCalcinosisPancreatic DiseasesGeneral MedicineMiddle Agedmedicine.diseasemedicine.anatomical_structurePancreatitisAdenocarcinomaFemaleRadiologyTomography X-Ray ComputedbusinessPancreasClinical Radiology
researchProduct

PANCREATIC CARCINOMA VERSUS CHRONIC FOCAL PANCREATITIS: CONTRAST-ENHANCED POWER DOPPLER ULTRASONOGRAPHY FINDINGS

2005

Background: We assessed the potential usefulness of contrast-enhanced power Doppler ultrasonography (US) for differentiating pancreatic carcinoma from chronic focal pancreatitis. Methods: Twenty-six consecutive patients with ductal carcinoma (n=16) and chronic focal pancreatitis (n=10) underwent power Doppler US examinations before and after intravenous injection of an air-based contrast agent (Levovist, Schering, Berlin, Germany). Final diagnosis was obtained by surgery in all patients. The following parameters before and after intravenous administration of contrast agent were evaluated for each lesion: number, morphology and course of the vessels within the lesion and time to maximum dete…

AdultMalemedicine.medical_specialtyPancreatic diseasechronic focal pancreatitiUrologyContrast MediaAdenocarcinomaDiagnosis DifferentialLesionPolysaccharidesInternal medicinemedicineCarcinomaHumansRadiology Nuclear Medicine and imagingAgedRetrospective Studiespower Doppler ultrasonographyRadiological and Ultrasound Technologypancreatic carcinomabusiness.industryultrasoundUltrasoundGastroenterologyUltrasonography DopplerGeneral MedicineMiddle AgedDuctal carcinomaHepatologymedicine.diseasePancreatic NeoplasmsPancreatitisChronic DiseaseInjections IntravenousPancreatitisFemaleRadiologymedicine.symptombusinessBlood Flow Velocitycontrast-enhanced ultrasoundContrast-enhanced ultrasound
researchProduct